• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Time to Bring Amicus Therapeutics Into the 'FOLD'

Shares of this biotech look ready for further strong gains.
By BRUCE KAMICH
Sep 08, 2017 | 10:09 AM EDT
Stocks quotes in this article: FOLD

The charts and indicators on Amicus Therapeutics, Inc. (FOLD)  appear bullish to me. I would look to position this stock from the long side, but let's take a look at the charts and indicators before clicking on "buy."

In this daily bar chart of FOLD, below, we can see a sideways trading range market or base pattern from last September until June of this year. Prices traded sideways around $7 with the declines below $7 being bought. How do I know or believe that those declines were bought by investors? Look at the On-Balance-Volume (OBV) line as it moves higher signaling more aggressive buying buy people. The volume of shares traded on down days was light but on up days it was stronger. That is the way the OBV indicator works. During the sideways trend the moving averages did not work, but in March and April they "kick in."

In March, FOLD rallied above the rising 50-day moving average line. In April a small pullback in FOLD holds above the rising 200-day moving average line. Prices retest the 200-day line successfully in May. The Moving Average Convergence Divergence (MACD) oscillator moved above the zero line back in February and recently turned up to a fresh go long signal.

Daily bar chart of FOLD from www.bigcharts.com
Daily bar chart of FOLD from www.bigcharts.com
 
In this weekly bar chart of FOLD, below, we can see that the base pattern in this stock is really much bigger than what we can see on a one-year daily chart. Here the pattern goes back to late 2015. The chart shows some old potential resistance in the $14-$19 area from back in 2015, but I am not that sure it will be a overhanging problem. Prices are above the rising 40-week moving average line. The weekly OBV line has been rising strongly since January of this year and confirms the rally. The weekly MACD oscillator is in a strong and rising bullish configuration.
 
Weekly bar chart of FOLD from www.bigcharts.com
Weekly bar chart of FOLD from www.bigcharts.com
 
In this Point and Figure chart of FOLD, below, we can see the base pattern, the breakout on the upside at $10 and a $28.50 potential price target.
 

Point and Figure chart of FOLD from www.stockcharts.com
Point and Figure chart of FOLD from www.stockcharts.com

Bottom line: I like these charts (above) and suggest buying FOLD here and on any weakness toward $13. Risk below $11.50. Buy more on strength to $15 or higher looking for gains in the next several months to the upper $20s.

More From Bruce Kamich:

  • Array BioPharma Seems to Be in a New Uptrend
  • Spark Therapeutics Is Ready to Catch Fire
  • Hit the 'Mother Lode' With Vale ADRs
  • Regeneron Pharmaceuticals Ready to Make All-Time Highs
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare | How-to | Stocks

More from Healthcare

Bearish Bets: 3 Stocks You Should Really Consider Shorting This Week

Bob Lang
May 28, 2023 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

These Small-Cap Biotech Stocks Have the Wind at Their Back

Bret Jensen
May 24, 2023 1:30 PM EDT

After getting a 'win' earlier this week on an acquisition, let's highlight a few similar names in my portfolio.

Why Are CRISPR Therapeutics Charts Saying 'Buy'?

Bruce Kamich
May 15, 2023 1:00 PM EDT

Here's where traders could go long.

Is It Time to Get Back Into CVS Health? Here's a Trade Idea

Stephen Guilfoyle
May 15, 2023 10:30 AM EDT

The fundamentals are not in tip-top shape, and now investors have reduced guidance to deal with.

Bearish Bets: 3 Well-Known Stocks You Should Consider Shorting This Week

Bob Lang
May 14, 2023 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:51 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Adjusting Your Trading Approach to Shifting Market...
  • 06:54 PM EDT CHRIS VERSACE

    AAP Podcast: A Tongue -- and a Market -- Twister: 'Get a Debt Deal Done'

    Listen in as the Action Alerts PLUS Podcast tackle...
  • 12:07 PM EDT STEPHEN GUILFOYLE

    Selling Some of This Surging AI-Related Stock

    This isn't the only name in the Stocks Under $10 p...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login